Drug intelligence / Profile preview

Capdoquin

Development stage: Unknown
Lead developer: NAEJA-RGM Pharmaceuticals
Modality: Small Molecules

Overview

Capdoquin is a small molecule topoisomerase inhibitor that was developed by Naeja-RGM Pharmaceutical for the treatment of bacterial infections. It targets bacterial topoisomerases, which are essential enzymes involved in maintaining the topological state of DNA during replication, transcription, and recombination. By inhibiting these enzymes, Capdoquin prevents bacterial cell division and growth. The development of Capdoquin has been discontinued, as indicated by the sponsor's pipeline information.

Targets

TOP (DNA topoisomerases)

Beyond the preview

Go deeper on Capdoquin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capdoquin.

Explore the full profile